Login to Your Account



Exelixis, BI Enter Autoimmune Agreement Worth up to $354M

By Catherine Hollingsworth


Monday, May 11, 2009
Exelixis Inc. and German drugmaker Boehringer Ingelheim GmbH entered a deal potentially worth $354 million to discover, develop and commercialize autoimmune disease therapies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription